WorldStage— For decades, Nigeria’s healthcare challenges have been reflected not only in the pressure on local hospitals and specialists, but also in the steady flow of Nigerians seeking treatment abroad.
The Nigeria Sovereign Investment Authority (NSIA), saw an opportunity in that challenge: rather than viewing healthcare solely as a social obligation, it could be approached as a long-term investment capable of generating both commercial value and measurable national impact.
That thinking shaped NSIA’s entry into the healthcare sector and ultimately led to the creation of Nigeria Sovereign Investment Authority Advanced Medical Services Limited (MedServe), the Authority’s wholly owned healthcare subsidiary.
The strategy was clear, develop specialised medical services that could reduce dependence on overseas treatment, retain expertise and capital within Nigeria, and expand access to quality healthcare for Nigerians.
Under the leadership of Aminu Umar-Sadiq, Managing Director and Chief Executive Officer of NSIA, the healthcare strategy has evolved beyond the construction of individual medical facilities into a broader effort to build sustainable healthcare capacity.
The focus now encompasses infrastructure, human capital, clinical research, international partnerships and the development of a healthcare ecosystem capable of delivering measurable outcomes over the long term.
From Vision to Healthcare Infrastructure
One of the most visible outcomes of the strategy is the MedServe–LUTH Cancer Centre (MLCC) in Lagos.
Commissioned in May 2019, the centre became the first oncology centre in Nigeria to offer 3D Conformal Radiotherapy and has since developed the largest concentration of radiotherapy equipment in West Africa.
Its importance became particularly apparent during the COVID-19 pandemic, when restrictions on international travel severely disrupted access to overseas medical treatment.
For cancer patients who would ordinarily have travelled abroad, the centre provided an important domestic alternative, allowing specialised treatment to continue despite the disruption to international travel.
The investment in oncology was complemented by the establishment of the MedServe Kano Diagnostic Centre (MKDC) and the MedServe Umuahia Diagnostic Centre (MUDC).
The centres introduced advanced radiology and pathology services to locations where access to such specialised diagnostic capabilities had previously been limited.
The scale of the intervention is reflected in the numbers.
Since inception, MLCC has delivered more than 25,000 radiotherapy sessions and 10,000 chemotherapy treatments to about 15,000 unique patients.
The centre has also recorded cases of Nigerians being referred back from overseas providers, reflecting growing confidence in the quality and cost-effectiveness of specialised treatment available locally.
Treatment costs remain significantly lower than comparable services abroad, in some cases costing less than half the international price.
According to NSIA, the interventions are estimated to have prevented more than US$200 million in foreign exchange outflows that would otherwise have been associated with overseas medical treatment and related expenses.
The impact extends beyond oncology.
By December 2025, more than 410,000 patients had received pathology and radiology services across the Kano and Umuahia diagnostic centres.
Beyond the numbers are outcomes that are harder to quantify but critical to healthcare development — earlier diagnosis, better clinical decision-making, specialised skills retained within Nigeria and reduced dependence on foreign healthcare providers.
Building More Than Medical Facilities
For NSIA, however, infrastructure is only one part of healthcare transformation.
A modern healthcare system also requires skilled professionals, research capabilities, knowledge transfer and connections with global institutions.
This has informed MedServe’s approach to oncology, a specialised field that remains relatively underdeveloped in Nigeria.
The subsidiary has focused on building a pipeline of oncology professionals, strengthening clinical research and trial capabilities relevant to African populations, and establishing relationships with leading international medical institutions.
One of the platforms created to support this objective is the annual Oncology Summit, which brings together clinicians, researchers, regulators and academics to exchange knowledge, promote professional development and explore opportunities for collaboration.
MedServe has also established partnerships with institutions including Memorial Sloan Kettering Cancer Center, the University of Maryland Medical Center and Bio Ventures for Global Health.
The partnerships are designed to support access to clinical trials and promote the adoption of innovative approaches in oncology, radiology and pathology.
MedServe has so far participated in two global cancer trials focusing on prostate and breast cancer.
The development is significant for Nigeria because participation in international research can help ensure that medical evidence and innovations are increasingly relevant to African populations.
It also strengthens the country’s capacity to contribute to, rather than simply consume, global healthcare research.
Taking Specialised Healthcare Beyond Major Cities
Having established a foundation in Lagos, Kano and Umuahia, MedServe is now entering another phase — expanding its geographical footprint.
The subsidiary has commenced a structured expansion programme covering 13 states, combining established urban centres such as Lagos, the Federal Capital Territory and Kaduna with other participating states including Oyo, Sokoto, Delta and Yobe.
The objective is to take specialised diagnostic and treatment services closer to Nigerians while building a geographically diversified healthcare network.
The expansion plan includes 13 new diagnostic centres, three additional oncology centres and three cardiac catheterisation laboratories.
The introduction of cardiac catheterisation also represents a new service line for the MedServe platform, extending its healthcare investment beyond oncology and diagnostics into cardiology.
But expanding the network is only part of the challenge. Maintaining equipment, service quality and operational efficiency across multiple locations will be equally important.
To address this, MedServe has established long-term partnerships with global equipment manufacturers Siemens and GE.
The partnerships cover equipment supply, maintenance, training and bulk procurement, with the objective of improving equipment uptime, maintaining consistent service standards and strengthening the sustainability of the expanding network.
Mobilising Capital for Healthcare
The financing behind the expansion also highlights NSIA’s broader role as an investment institution.
MedServe secured up to US$24.3 million in blended financing from the International Finance Corporation (IFC) and the International Development Association (IDA).
The financing structure is intended to reduce the cost of capital while supporting the affordability of healthcare services.
More broadly, the transaction demonstrates how public-sector investment institutions can use their balance sheets and partnerships to mobilise additional capital into sectors where funding constraints have historically limited development.
For Nigeria’s healthcare sector, attracting development finance and international partnerships could be critical to scaling infrastructure without placing the entire burden of investment on public resources.
From Medical Tourism to Domestic Capacity
Nigeria’s healthcare challenge has traditionally been associated with the significant number of citizens travelling abroad for specialised treatment.
NSIA’s healthcare strategy seeks to change that narrative by demonstrating that specialised, high-quality and affordable medical services can be developed and sustained domestically.
The objective is not simply to build hospitals or diagnostic centres.
It is to create an integrated system in which infrastructure is supported by skilled professionals, research, technology, international partnerships and sustainable financing.
The commissioning of new centres under the expansion programme, scheduled to begin from mid-2026, will provide another test of the model.
If successful, the impact will extend beyond the number of facilities built.
It will be measured by the number of patients treated locally, the expertise retained in the country, the foreign exchange saved, the investments mobilised and the extent to which Nigerians can access specialised treatment without leaving the country.
For NSIA, that is ultimately the broader measure of its healthcare investment.
The journey from vision to impact is still unfolding, but the direction is increasingly clear: deploy patient capital, build sustainable capacity, leverage global partnerships and create a healthcare system capable of delivering value over the long term.
In that model, healthcare investment is not simply about infrastructure.
It is about building national capability and ensuring that more Nigerians can access quality, dignified and specialised healthcare at home.
